Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) reached a new 52-week high on Wednesday . The company traded as high as $540.00 and last traded at $527.74, with a volume of 263 shares. The stock had previously closed at $525.93.
Wall Street Analyst Weigh In
Several research firms recently issued reports on IDXX. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Leerink Partners raised their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research note on Wednesday. Stifel Nicolaus lifted their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Finally, Morgan Stanley boosted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $546.00.
View Our Latest Stock Analysis on IDEXX Laboratories
IDEXX Laboratories Trading Up 0.1%
The company's fifty day simple moving average is $466.92 and its two-hundred day simple moving average is $442.89. The company has a market capitalization of $42.18 billion, a price-to-earnings ratio of 49.16, a price-to-earnings-growth ratio of 3.41 and a beta of 1.55. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company's revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.71 earnings per share. Research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director M Anne Szostak sold 1,046 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $513.74, for a total value of $537,372.04. Following the completion of the transaction, the director now directly owns 262 shares of the company's stock, valued at approximately $134,599.88. This represents a 79.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.98% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. MorganRosel Wealth Management LLC acquired a new position in IDEXX Laboratories during the 1st quarter worth approximately $26,000. Hurley Capital LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth $29,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. grew its position in IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after purchasing an additional 30 shares in the last quarter. Finally, Colonial Trust Co SC increased its stake in IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after buying an additional 39 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.
IDEXX Laboratories Company Profile
(
Get Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Read More
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
